Literature DB >> 16629406

Inhibition of beta-1,3-glucan synthase and cell growth of Cryptococcus species by recombinant single-chain anti-idiotypic antibodies.

Dakshnamurthy Selvakumar1, Masahiko Miyamoto, Yasuhiro Furuichi, Tadazumi Komiyama.   

Abstract

Recombinant single-chain fragment variable (scFv) anti-idiotypic antibodies were produced to represent the internal image of a HM-1 killer toxin, which is characterized by a wide spectrum of anti-fungal activity through inhibiting beta-1,3-glucan synthase (GS). We examined if scFv antibodies are active against Cryptococcus species, a human pathogen of increasing medical importance. The anti-cryptococcal activity of scFv antibodies and HM-1 were assessed by MIC analysis for C. neoformans IFM 40215 and C. albidus NBRC 0612 cells. The scFv antibodies had strong anti-cryptococcal activity in vitro with IC50 at 1.07 x 10(-7) to 2.60 x 10(-7) M for C. neoformans and C. albidus. Furthermore, the scFv antibodies potentially inhibited GS of C. neoformans with IC50 at 1.27 x 10(-7) to 2.27 x 10(-7) M. Both the anti-fungal and anti-GS activities of the scFv antibodies were markedly neutralized by the monoclonal antibody that neutralizes HM-1 killer toxin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629406     DOI: 10.1038/ja.2006.10

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  Inhibition of fungal beta-1,3-glucan synthase and cell growth by HM-1 killer toxin single-chain anti-idiotypic antibodies.

Authors:  Dakshnamurthy Selvakumar; Masahiko Miyamoto; Yasuhiro Furuichi; Tadazumi Komiyama
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.

Authors:  Anna Rachini; Donatella Pietrella; Patrizia Lupo; Antonella Torosantucci; Paola Chiani; Carla Bromuro; Carla Proietti; Francesco Bistoni; Antonio Cassone; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2007-07-02       Impact factor: 3.441

Review 3.  Wickerhamomyces Yeast Killer Toxins' Medical Applications.

Authors:  Laura Giovati; Tecla Ciociola; Tiziano De Simone; Stefania Conti; Walter Magliani
Journal:  Toxins (Basel)       Date:  2021-09-15       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.